Synapse - Robert Motzer

Results (123)

Sarcomatoid-variant renal cell carcinoma: Treatment outcome and survival in advanced disease

Journal Article

Molina, A. M.; Tickoo, S. K.; Ishill, N.; Trinos, M. J.; Schwartz, L. H.; Patil, S.; Feldman, D. R.; Reuter, V. E.; Russo, P.; Motzer, R. J.
American Journal of Clinical Oncology (2011)

Fulltext@MSK | Save

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma

Journal Article

Patil, S.; Figlin, R. A.; Hutson, T. E.; Michaelson, M. D.; Negrier, S.; Kim, S. T.; Huang, X.; Motzer, R. J.
Annals of Oncology (2011)

Fulltext@MSK | Save

TWiST analysis to estimate overall benefit for metastatic renal cell carcinoma (mRCC) patients (pts) treated in a phase III trial of sunitinib versus interferon-alfa (IFN-alpha)

Meeting Abstract

Patil, S.; Figlin, R. A.; Hutson, T. E.; Michaelson, D.; Negrier, S.; Kim, S. T.; Huang, X.; Motzer, R. J.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Long-term responders to sunitinib therapy for metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Molina, A. M.; Jia, X.; Ginsberg, M. S.; Velasco, S.; Feldman, D. R.; Patil, S.; Motzer, R. J.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Progression-free survival (PFS) as a new endpoint for designing phase II trials in patients with refractory germ cell tumors (GCT)

Meeting Abstract

Feldman, D. R.; Patil, S.; Trinos, M. J.; Carousso, M.; Ginsberg, M. S.; Sheinfeld, J.; Bajorin, D. F.; Bosl, G. J.; Motzer, R. J.
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: Results and prognostic factor analysis

Journal Article

Feldman, D. R.; Sheinfeld, J.; Bajorin, D. F.; Fischer, P.; Turkula, S.; Ishill, N.; Patil, S.; Bains, M.; Reich, L. M.; Bosl, G. J.; more...
Journal of Clinical Oncology (2010)

Fulltext@MSK | Save

Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients: Implications for clinical trial design and interpretation

Journal Article

Patil, S.; Ishill, N.; Deluca, J.; Motzer, R. J.
Cancer (2010)

Fulltext@MSK | Save

Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors

Journal Article

Feldman, D. R.; Turkula, S.; Ginsberg, M. S.; Ishill, N.; Patil, S.; Carousso, M.; Bosl, G. J.; Motzer, R. J.
Investigational New Drugs (2010)

Fulltext@MSK | Save

Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)

Meeting Abstract

Patil, S.; Figlin, R. A.; Hutson, T. E.; Michaelson, M. D.; Negrier, S.; Kim, S. T.; Huang, X.; Motzer, R. J.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

Treatment outcome and survival for patients (pts) with sarcomatoid-variant metastatic renal cell carcinoma (RCC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience

Meeting Abstract

Molina, A. M.; Tickoo, S. K.; Ishill, N.; Trinos, M. J.; Schwartz, L. H.; Russo, P.; Feldman, D. R.; Patil, S.; Motzer, R. J.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save